- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02398890
Follow-up of Oncology Patients After Hospitalization in ICU (SALTO)
"Purpose: The overall prognosis of oncology patients admitted to intensive care has improved greatly in recent years, leading to a wider admission policy. Due to a decrease in mortality in intensive care, more and more patients returning oncological circuit for the continuation of treatment of the underlying disease The existence of sequelae after the ICU (Intensive Care Unit) stay, whether renal, cardiac, respiratory or other, may influence the continuation of the optimal anti -cancer treatments and thus reduce the chances of recovery or evolution without tumor progression. However, no studies have evaluated the effects of resuscitation on subsequent cancer treatment strategies. It would thus become better appreciate the long-term oncology patients discharged alive from the hospital after a stay in intensive care.
Main purpose of research :
Assess the feasibility of a anti-tumor therapy for patients with progressive solid tumors, after an intensive care stay for other reason than elective surgery monitoring or securing an invasive procedure. The possibility of making an anti -cancer treatment will be evaluated by the treating oncologist and classified total, partial or absent from that defined before or during the ICU stay
Secondary objective of the research :
Evaluate the percentage of patients discharged alive from the ICU and dying in the hospital.
Evaluate survival, lifestyle and physical and psychological effects of these patients after discharge from the hospital over a period of one year. It is understood that all these secondary endpoints will interfere with the existence of an evolutionary neoplasia not only with the ICU stay. They will therefore be interpreted with caution.
Study Type: observational Study Design: Prognostic study of routine care, national, prospective, cohort type "
Studieöversikt
Detaljerad beskrivning
"Nature of evaluated care: Longitudinal follow-up of post- resuscitation intensive care Concerned population: adult patients with active solid tumor out alive from the ICU and following-up in oncology in the same hospital as the resuscitator investigator.
Main objective: Measure the influence of ICU for patients with solid cancers to continue with optimal anti -cancer treatment, defined before or during hospitalization in intensive care.
Secondary objective: Assess the physical and psychological consequences of ICU stay of patients Evaluation criteria : Primary endpoint: proportion of patients living, out from ICU and hospital, can receive optimal cancer treatment later.
Research Methodology : Prognostic study of routine care, national, prospective, cohort type."
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Montfermeil, Frankrike, 93370
- CHI Le Raincy-Montfermeil
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion criteria:
- Patient with progressive solid tumor hospitalized in intensive care and got out alive
- Oncology patients followed in the same hospital as the investigator resuscitator
- Age ≥ 18 years
- Affiliate of social insurance
- Agree to participate
Exclusion criteria :
- Patient hospitalized for programed surgery
- Hospitalization for securing procedure
- Pregnancy or breastfeeding woman
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Proportion of patients with cancer admitted in ICU who will be eligible for optimal anti-cancer treatment after discharge from ICU
Tidsram: Months12
|
Months12
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- KI120906
- 2013-A00683-42 (Annan identifierare: ANSM)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på rutinvård
-
Chunrui LiNanjing IASO Biotechnology Co., LtdRekryteringPlasmacellleukemi | Återfall/refraktärt multipelt myelomKina
-
Cellular Biomedicine Group Ltd.The First Affiliated Hospital with Nanjing Medical UniversityAvslutadEn fas 1-studie som utvärderar säkerhet och effekt av C-CAR011-behandling hos DLBCL-ämnen (C-CAR011)Refraktärt diffust stort B-cellslymfomKina
-
Nexcella Inc.Har inte rekryterat ännuLätt kedja (AL) amyloidosFörenta staterna
-
Second Affiliated Hospital, School of Medicine,...RekryteringÅterfall och refraktärt B-cellslymfomKina
-
Second Affiliated Hospital, School of Medicine,...RekryteringB-cells non-Hodgkin lymfomKina
-
University of California, San FranciscoIndragenLymfom | Leukemi | Plasmacelldyskrasi
-
Hebei Senlang Biotechnology Inc., Ltd.RekryteringLymfom | Multipelt myelom | Akut lymfoblastisk leukemiKina
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...IndragenAkut lymfoblastisk leukemi | Non-hodgkin lymfomFörenta staterna
-
Nanjing IASO Biotechnology Co., Ltd.Ruijin HospitalRekryteringPlasmacellleukemi | Återfall/refraktärt multipelt myelomKina
-
Zhejiang UniversityYake Biotechnology Ltd.RekryteringMultipelt myelom | Ny diagnostumörKina